(Total Views: 688)
Posted On: 01/12/2020 5:29:49 AM
Post# of 155807
Leronlimab is in a great position according to the first sentence of this article.
T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors
"CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors. For genuine success against solid tumors, adoptive cellular therapy (ACT) must move in a different direction, says Steven A. Rosenberg, MD, PhD, chief of surgery in the National Cancer Institute and a 2013 winner of the Giants of Cancer Care® award for immunotherapy."
https://www.onclive.com/publications/oncology...lid-tumors
T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors
"CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors. For genuine success against solid tumors, adoptive cellular therapy (ACT) must move in a different direction, says Steven A. Rosenberg, MD, PhD, chief of surgery in the National Cancer Institute and a 2013 winner of the Giants of Cancer Care® award for immunotherapy."
https://www.onclive.com/publications/oncology...lid-tumors
(0)
(0)
